General Information of Drug (ID: DMTIQF3)

Drug Name
Treprostinil
Synonyms
Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Approved [1]
Pulmonary hypertension BB01 Approved [2]
Critical limb ischemia BD4Y Investigative [2]
Peripheral vascular disease BD4Z Investigative [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 390.5
Logarithm of the Partition Coefficient (xlogp) 4.5
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 100% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 10.7 mL/min/kg [4]
Elimination
4% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 4 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.1456 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [4]
Vd
The volume of distribution (Vd) of drug is 14 L []
Chemical Identifiers
Formula
C23H34O5
IUPAC Name
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
Canonical SMILES
CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
InChI
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
InChIKey
PAJMKGZZBBTTOY-ZFORQUDYSA-N
Cross-matching ID
PubChem CID
6918140
ChEBI ID
CHEBI:50861
CAS Number
81846-19-7
DrugBank ID
DB00374
TTD ID
D01WUA
INTEDE ID
DR1632
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostacyclin receptor (PTGIR) TTOFYT1 PI2R_HUMAN Agonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [7]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pulmonary arterial hypertension
ICD Disease Classification BB01.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostacyclin receptor (PTGIR) DTT PTGIR 7.12E-02 -0.13 -0.33
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.25E-03 -4.98E-01 -6.49E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Treprostinil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Treprostinil and Cilostazol. Arterial occlusive disease [BD40] [10]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Treprostinil and Linezolid. Bacterial infection [1A00-1C4Z] [11]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Treprostinil caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Treprostinil and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [10]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Treprostinil and Pentosan polysulfate. Chronic pain [MG30] [13]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Treprostinil and Phenylbutazone. Chronic pain [MG30] [10]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Treprostinil and Ketoprofen. Chronic pain [MG30] [10]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Treprostinil and Levomilnacipran. Chronic pain [MG30] [14]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Treprostinil and Anisindione. Coagulation defect [3B10] [10]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Treprostinil and Regorafenib. Colorectal cancer [2B91] [15]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Treprostinil and Ardeparin. Coronary thrombosis [BA43] [16]
Mifepristone DMGZQEF Moderate Decreased metabolism of Treprostinil caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [17]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Treprostinil caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [18]
MK-8228 DMOB58Q Moderate Decreased metabolism of Treprostinil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [12]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Treprostinil and Danaparoid. Deep vein thrombosis [BD71] [16]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Treprostinil and Rivaroxaban. Deep vein thrombosis [BD71] [19]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Treprostinil and Sertraline. Depression [6A70-6A7Z] [14]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Treprostinil and Fluoxetine. Depression [6A70-6A7Z] [14]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Treprostinil and Vilazodone. Depression [6A70-6A7Z] [14]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Treprostinil and Paroxetine. Depression [6A70-6A7Z] [14]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Treprostinil and Selegiline. Depression [6A70-6A7Z] [11]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Treprostinil and Vortioxetine. Depression [6A70-6A7Z] [14]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Treprostinil and Duloxetine. Depression [6A70-6A7Z] [14]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Treprostinil and Isocarboxazid. Depression [6A70-6A7Z] [11]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Treprostinil and Milnacipran. Depression [6A70-6A7Z] [14]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Treprostinil and Escitalopram. Depression [6A70-6A7Z] [14]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Treprostinil and Tranylcypromine. Depression [6A70-6A7Z] [11]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Treprostinil and Desvenlafaxine. Depression [6A70-6A7Z] [14]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Treprostinil and Phenelzine. Depression [6A70-6A7Z] [11]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Treprostinil and Clomipramine. Depression [6A70-6A7Z] [14]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Treprostinil and Heme. Discovery agent [N.A.] [20]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Treprostinil and Apigenin. Discovery agent [N.A.] [21]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Treprostinil and PMID28870136-Compound-49. Discovery agent [N.A.] [10]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Treprostinil and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [14]
Phenobarbital DMXZOCG Moderate Increased metabolism of Treprostinil caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Carbamazepine DMZOLBI Moderate Increased metabolism of Treprostinil caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Treprostinil and Mefenamic acid. Female pelvic pain [GA34] [10]
Ripretinib DM958QB Moderate Decreased metabolism of Treprostinil caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Treprostinil and Avapritinib. Gastrointestinal stromal tumour [2B5B] [15]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Treprostinil and Sulfinpyrazone. Gout [FA25] [10]
Rifampin DMA8J1G Moderate Increased metabolism of Treprostinil caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [23]
Rifapentine DMCHV4I Moderate Increased metabolism of Treprostinil caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Treprostinil and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [24]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Treprostinil caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [12]
Teriflunomide DMQ2FKJ Moderate Decreased metabolism of Treprostinil caused by Teriflunomide mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [12]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Treprostinil and Dipyridamole. Hypertension [BA00-BA04] [10]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Treprostinil and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [10]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Treprostinil and Acalabrutinib. Mature B-cell lymphoma [2A85] [25]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Treprostinil and Ibrutinib. Mature B-cell lymphoma [2A85] [22]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Treprostinil and Ponatinib. Mature B-cell lymphoma [2A85] [26]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Treprostinil caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [12]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Treprostinil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [22]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Treprostinil and Panobinostat. Multiple myeloma [2A83] [27]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Treprostinil and Ozanimod. Multiple sclerosis [8A40] [11]
Fedratinib DM4ZBK6 Moderate Increased risk of bleeding by the combination of Treprostinil and Fedratinib. Myeloproliferative neoplasm [2A20] [10]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Treprostinil and Dasatinib. Myeloproliferative neoplasm [2A20] [28]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Treprostinil and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [13]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Treprostinil and Prasugrel. Myocardial infarction [BA41-BA43] [10]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Treprostinil and Vorapaxar. Myocardial infarction [BA41-BA43] [10]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Treprostinil and Tirofiban. Myocardial infarction [BA41-BA43] [10]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Treprostinil and Sibutramine. Obesity [5B80-5B81] [14]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Treprostinil and Dexfenfluramine. Obesity [5B80-5B81] [14]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Treprostinil and Diclofenac. Osteoarthritis [FA00-FA05] [10]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Treprostinil and Nepafenac. Osteoarthritis [FA00-FA05] [29]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Treprostinil and Naproxen. Osteoarthritis [FA00-FA05] [10]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Treprostinil and MK-4827. Ovarian cancer [2C73] [15]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Treprostinil and Aspirin. Pain [MG30-MG3Z] [10]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Treprostinil and Etodolac. Pain [MG30-MG3Z] [10]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Treprostinil and Ibuprofen. Pain [MG30-MG3Z] [10]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Treprostinil and Nabumetone. Pain [MG30-MG3Z] [10]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Treprostinil and Piroxicam. Pain [MG30-MG3Z] [10]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Treprostinil and Safinamide. Parkinsonism [8A00] [11]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Treprostinil and Rasagiline. Parkinsonism [8A00] [11]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Treprostinil and Choline salicylate. Postoperative inflammation [1A00-CA43] [10]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Treprostinil and Ketorolac. Postoperative inflammation [1A00-CA43] [10]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Treprostinil and Bromfenac. Postoperative inflammation [1A00-CA43] [10]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Treprostinil caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [12]
Sorafenib DMS8IFC Moderate Decreased metabolism of Treprostinil caused by Sorafenib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [12]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Treprostinil and Salsalate. Rheumatoid arthritis [FA20] [10]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Treprostinil and Meloxicam. Rheumatoid arthritis [FA20] [10]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Treprostinil and Sulindac. Rheumatoid arthritis [FA20] [10]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Treprostinil and Oxaprozin. Rheumatoid arthritis [FA20] [10]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Treprostinil and Flurbiprofen. Rheumatoid arthritis [FA20] [10]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Treprostinil and Fenoprofen. Rheumatoid arthritis [FA20] [10]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Treprostinil and Tolmetin. Rheumatoid arthritis [FA20] [10]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Treprostinil and Salicyclic acid. Seborrhoeic dermatitis [EA81] [10]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Treprostinil and Warfarin. Supraventricular tachyarrhythmia [BC81] [10]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Treprostinil and Plicamycin. Testicular cancer [2C80] [10]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Treprostinil and Caplacizumab. Thrombocytopenia [3B64] [10]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Treprostinil and Apixaban. Thrombosis [DB61-GB90] [15]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Treprostinil and Cangrelor. Thrombosis [DB61-GB90] [10]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Treprostinil and Brilinta. Thrombosis [DB61-GB90] [15]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Treprostinil and Clopidogrel. Thrombosis [DB61-GB90] [10]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Treprostinil and Cabozantinib. Thyroid cancer [2D10] [30]
Trimethoprim DMM7CHK Moderate Decreased metabolism of Treprostinil caused by Trimethoprim mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [12]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Treprostinil and Betrixaban. Venous thromboembolism [BD72] [31]
⏷ Show the Full List of 96 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5820).
2 Treprostinil FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
7 Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34.
8 FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
9 Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res. 2010 Jul 23;107(2):252-62. doi: 10.1161/CIRCRESAHA.109.209940. Epub 2010 Jun 3.
10 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
11 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
12 Product Information. Remodulin (treprostinil). United Therapeutics Corp, Silver Spring, MD.
13 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
14 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
17 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
18 Cerner Multum, Inc. "Canadian Product Information.".
19 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
20 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
21 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
22 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
23 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
24 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
25 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
26 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
29 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
30 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
31 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.